Synthesis and Biological Activity of a Novel Series of 6-Substituted Thieno[2,3-d]pyrimidine Antifolate Inhibitors of Purine Biosynthesis with Selectivity for High Affinity Folate Receptors over the Reduced Folate Carrier and Proton-Coupled Folate Transporter for Cellular Entry†
- 16 April 2009
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 52 (9) , 2940-2951
Abstract
A series of seven 2-amino-4-oxo-6-substituted thieno[2,3-d]pyrimidines with bridge length variations (from 2 to 8 carbon atoms) were synthesized as selective folate receptor (FR) α and β substrates and as antitumor agents. The syntheses were accomplished from appropriate allylalcohols and 4-iodobenzoate to afford the aldehydes, which were converted to the appropriate 2-amino-4-carbethoxy-5-substituted thiophenes 23−29. Cyclization with chloroformamidine afforded the thieno[2,3-d]pyrimidines 30−36, which were hydrolyzed and coupled with diethyl-l-glutamate, followed by saponification, to give the target compounds 2−8. Compounds 3−6 were potent growth inhibitors (IC50 4.7−334 nM) of human tumor cells (KB and IGROV1) that express FRs. In addition, compounds 3−6 inhibited the growth of Chinese hamster ovary (CHO) cells that expressed FRs but not the reduced folate carrier (RFC) or proton-coupled folate transporter (PCFT). However, the compounds were inactive toward CHO cells that lacked FRs but contained either the RFC or PCFT. By nucleoside and 5-amino-4-imidazole carboxamide (AICA) protection studies, along with in vitro and in situ enzyme activity assays, the mechanism of antitumor activity was identified as the dual inhibition of glycinamide ribonucleotide formyltransferase and, likely, AICA ribonucleotide formyltransferase. The dual inhibitory activity of the active thieno[2,3-d]pyrimidine antifolates and the FR specificity represent unique mechanistic features for these compounds distinct from all other known antifolates. The potent inhibitory effects of compounds 3−6 toward cells expressing FRs but not PCFT provide direct evidence that cellular uptake of this series of compounds by FRs does not depend on the presence of PCFT and argues that direct coupling between these transporters is not obligatory.Keywords
This publication has 37 references indexed in Scilit:
- A Role for the Proton-coupled Folate Transporter (PCFT-SLC46A1) in Folate Receptor-mediated EndocytosisJournal of Biological Chemistry, 2009
- Synthesis and Discovery of High Affinity Folate Receptor-Specific Glycinamide Ribonucleotide Formyltransferase Inhibitors with Antitumor ActivityJournal of Medicinal Chemistry, 2008
- The molecular identity and characterization of a Proton-Coupled Folate Transporter—PCFT; biological ramifications and impact on the activity of pemetrexed—12 06 06Cancer and Metastasis Reviews, 2007
- Human reduced folate carrier: translation of basic biology to cancer etiology and therapyCancer and Metastasis Reviews, 2007
- The folate receptor: What does it promise in tissue-targeted therapeutics?Cancer and Metastasis Reviews, 2007
- FDA Drug Approval Summaries: Pemetrexed (Alimta®)The Oncologist, 2004
- ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancerEuropean Journal of Cancer, 1995
- A potent antitumour quinazoline inhibitor of thymidylate synthetase: Synthesis, biological properties and therapeutic results in mice1981
- 2,4-Diaminothieno[2,3-d]pyrimidines as antifolates and antimalarials. 3. Synthesis of 5,6-disubstituted derivatives and related tetracyclic analogsJournal of Medicinal Chemistry, 1973
- Inhibition of Estrogen-induced Growth in the Genital Tract of the Female Chick by a Purine Antagonist; Reversal by AdenineScience, 1949